NASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Forecast, Price & News $14.40 +0.30 (+2.13%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$13.75▼$14.6650-Day Range$8.48▼$15.5052-Week Range$2.12▼$15.82Volume580,959 shsAverage Volume741,573 shsMarket Capitalization$1.11 billionP/E RatioN/ADividend YieldN/APrice Target$13.44 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Avadel Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside6.7% Downside$13.44 Price TargetShort InterestHealthy4.36% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 7 Articles This WeekInsider TradingAcquiring Shares$36,900 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.29) to ($0.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.78 out of 5 starsMedical Sector156th out of 986 stocksPharmaceutical Preparations Industry64th out of 478 stocks 1.5 Analyst's Opinion Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.44, Avadel Pharmaceuticals has a forecasted downside of 6.7% from its current price of $14.40.Amount of Analyst CoverageAvadel Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.36% of the outstanding shares of Avadel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently decreased by 13.88%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVDL. Previous Next 2.8 News and Social Media Coverage News SentimentAvadel Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Avadel Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $36,900.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.00% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions50.81% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($1.29) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -6.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -6.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Avadel Pharmaceuticals (NASDAQ:AVDL) StockAvadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on the approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded in 1990 and is headquartered in Dublin, Ireland.Read More Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVDL Stock News HeadlinesJune 5, 2023 | finance.yahoo.comAvadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ™ (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with NarcolepsyJune 3, 2023 | fool.comAvadel Pharmaceuticals Plc (NASDAQ: AVDL)June 6, 2023 | Chaikin Analytics (Ad)Famous Wall Street Crash System Flashes REDHundreds of banks, hedge funds, and brokerages have paid $5,000 a month to access these alerts. Because when this system flashes on U.S. stocks, huge gains – and losses – can follow.June 2, 2023 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) Shares Up 4.6%May 31, 2023 | finance.yahoo.comAvadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023May 31, 2023 | finance.yahoo.comAvadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023May 30, 2023 | markets.businessinsider.comWhat 11 Analyst Ratings Have To Say About Avadel PharmaceuticalsMay 28, 2023 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) Shares Cross Above Two Hundred Day Moving Average of $9.10June 6, 2023 | Chaikin Analytics (Ad)Famous Wall Street Crash System Flashes REDHundreds of banks, hedge funds, and brokerages have paid $5,000 a month to access these alerts. Because when this system flashes on U.S. stocks, huge gains – and losses – can follow.May 21, 2023 | finance.yahoo.comIndependent Director of Avadel Pharmaceuticals Picks Up 8.4% More Stock \May 20, 2023 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) Trading Down 3.8%May 20, 2023 | americanbankingnews.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Receives $13.44 Consensus Target Price from BrokeragesMay 18, 2023 | seekingalpha.comAvadel Pharmaceuticals (AVDL) Investor Presentation - SlideshowMay 17, 2023 | seekingalpha.comAvadel Pharmaceuticals: Lumryz Approved, Launch Expected June 2023 And We Remain BullishMay 12, 2023 | americanbankingnews.comLinda Palczuk Buys 2,500 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL) StockMay 5, 2023 | finance.yahoo.comWhy Shares of Avadel Soared This WeekMay 4, 2023 | seekingalpha.comAvadel Pharmaceuticals GAAP EPS of -$0.48 misses by $0.10May 4, 2023 | finance.yahoo.comAvadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 4, 2023 | americanbankingnews.comQ1 2023 Earnings Estimate for Avadel Pharmaceuticals plc (NASDAQ:AVDL) Issued By HC WainwrightMay 4, 2023 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) PT Raised to $14.00May 4, 2023 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) Sees Unusually-High Trading Volume After Analyst UpgradeMay 3, 2023 | msn.comLifeSci Capital Maintains Avadel Pharmaceuticals plc - ADR (AVDL) Outperform RecommendationMay 3, 2023 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Shares Could Be 45% Below Their Intrinsic Value EstimateMay 3, 2023 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) PT Raised to $16.00May 2, 2023 | msn.comOppenheimer Maintains Avadel Pharmaceuticals plc - ADR (AVDL) Outperform RecommendationMay 2, 2023 | msn.comNeedham Maintains Avadel Pharmaceuticals plc - ADR (AVDL) Buy RecommendationMay 2, 2023 | markets.businessinsider.comAnalyst Expectations for Avadel Pharmaceuticals's FutureSee More Headlines AVDL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVDL Company Calendar Last Earnings3/30/2023Today6/05/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVDL CUSIPN/A CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees66Year Founded2015Price Target and Rating Average Stock Price Forecast$13.44 High Stock Price Forecast$20.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside-6.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-137,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-2,266.74% Return on Assets-74.87% Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio1.38 Sales & Book Value Annual Sales$22.33 million Price / Sales49.51 Cash FlowN/A Price / Cash FlowN/A Book Value($0.34) per share Price / Book-42.35Miscellaneous Outstanding Shares76,770,000Free Float73,697,000Market Cap$1.11 billion OptionableOptionable Beta1.43 Social Links Key ExecutivesGregory J. DivisChief Executive Officer & DirectorScott MackeVice President-Supply Chain & OperationsThomas S. McHughChief Financial Officer & Senior Vice PresidentJason VaughnSenior Vice President-Technical OperationsJennifer GudemanVice President-Medical & Clinical AffairsKey CompetitorsDeciphera PharmaceuticalsNASDAQ:DCPHOPKO HealthNASDAQ:OPKMirum PharmaceuticalsNASDAQ:MIRMSummit TherapeuticsNASDAQ:SMMTMerusNASDAQ:MRUSView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 94,421 shares on 5/22/2023Ownership: 0.284%Altium Capital Management LPBought 500,000 shares on 5/16/2023Ownership: 0.644%Susquehanna International Group LLPSold 83,100 shares on 5/16/2023Ownership: 0.000%State Street CorpBought 10,286 shares on 5/16/2023Ownership: 0.122%Geode Capital Management LLCBought 924 shares on 5/16/2023Ownership: 0.103%View All Insider TransactionsView All Institutional Transactions AVDL Stock - Frequently Asked Questions Should I buy or sell Avadel Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares. View AVDL analyst ratings or view top-rated stocks. What is Avadel Pharmaceuticals' stock price forecast for 2023? 7 Wall Street research analysts have issued 1 year target prices for Avadel Pharmaceuticals' shares. Their AVDL share price forecasts range from $5.00 to $20.00. On average, they predict the company's stock price to reach $13.44 in the next twelve months. This suggests that the stock has a possible downside of 6.7%. View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts. How have AVDL shares performed in 2023? Avadel Pharmaceuticals' stock was trading at $7.16 at the start of the year. Since then, AVDL stock has increased by 101.1% and is now trading at $14.40. View the best growth stocks for 2023 here. Are investors shorting Avadel Pharmaceuticals? Avadel Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 3,350,000 shares, a drop of 13.9% from the April 30th total of 3,890,000 shares. Based on an average daily trading volume, of 916,600 shares, the days-to-cover ratio is presently 3.7 days. View Avadel Pharmaceuticals' Short Interest. When is Avadel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our AVDL earnings forecast. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) posted its quarterly earnings data on Thursday, March, 30th. The company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.14. What ETFs hold Avadel Pharmaceuticals' stock? ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY). What is Avadel Pharmaceuticals' stock symbol? Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL." Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Gendell Jeffrey L (6.83%), Wealth Effects LLC (3.22%), Brandes Investment Partners LP (1.86%), Samsara BioCapital LLC (1.82%), Renaissance Technologies LLC (1.06%) and Bank of America Corp DE (0.89%). Insiders that own company stock include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avadel Pharmaceuticals' stock price today? One share of AVDL stock can currently be purchased for approximately $14.40. How much money does Avadel Pharmaceuticals make? Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $1.11 billion and generates $22.33 million in revenue each year. The company earns $-137,460,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. How can I contact Avadel Pharmaceuticals? Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 901-5201, via email at investors@avadel.com, or via fax at 353-1526-1077. This page (NASDAQ:AVDL) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.